Julia Weber-Arden
University of Freiburg
8 Papers
Julia Weber-Arden is an academic researcher from University of Freiburg. The author has contributed to research in topics: Internal medicine & Canakinumab. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Pos1570 long-term safety and effectiveness of canakinumab in familial mediterranean fever (fmf) – 36-month data from the reliance registry
J. Henes,Norbert Blank,T. Krickau,Alexis Pankow,Ivan Foeldvari,Frank Dressler,Gerd Horneff,Tilmann Kallinich,Prasad T. Oommen,Franziska Meier,Frank Weller-Heinemann,Birgit Kortus-Goetze,Markus Hufnagel,Juergen Rech,I. Andreica,Julia Weber-Arden,Jasmin B Kuemmerle-Deschner +16 more
TL;DR: The RELIANCE registry as discussed by the authors evaluated the long-term efficacy and safety of CAN under routine clinical practice conditions in pediatric (age ≥ 2 years) and adult patients with FMF and other recurrent hereditary fever conditions.
1
Pos1374 long-term safety of canakinumab in patients with autoinflammatory diseases - interim analysis of the reliance registry
Jasmin B Kuemmerle-Deschner,J. Henes,Birgit Kortus-Goetze,Tilmann Kallinich,Prasad T. Oommen,Juergen Rech,T. Krickau,Frank Weller-Heinemann,Gerd Horneff,Ales Janda,Ivan Foeldvari,C. Schuetz,Frédéric Dressler,Michael Forte,Mark Hufnagel,Frank Meier,Marilyn L Fiene,Julia Weber-Arden,Norbert Blank +18 more
TL;DR: The present study explores the long-term efficacy and safety of CAN in routine clinical practice conditions in pediatric and adult patients with CAPS (cryopyrin-associated periodic syndromes), FMF (familial Mediterranean fever), TRAPS (tumor necrosis factor receptor- associated periodic syndrome) and HIDS/MKD (hyperimmunoglobulinemia D syndrome/mevalonate kinase deficiency) through the RELIANCE study.
Pos0220 long-term safety and effectiveness of canakinumab in cryopyrin-associated periodic syndromes – 36-month data from the reliance registry
Jasmin B Kuemmerle-Deschner,Birgit Kortus-Goetze,Prasad T. Oommen,Ales Janda,Juergen Rech,Catharina Schuetz,Tilmann Kallinich,Frank Weller-Heinemann,Gerd Horneff,Ivan Foeldvari,F Meier,Michael Forte,T. Krickau,Julia Weber-Arden,Norbert Blank +14 more
TL;DR: This prospective, non-interventional, observational study with a 3-year follow-up enrolls patients in Germany with clinically confirmed diagnoses of CAPS routinely receiving CAN to explore long-term safety and effectiveness of CAN under routine clinical practice conditions.
Long-term Effectiveness and Safety of Canakinumab in Patients with TRAPS: Analysis of the RELIANCE Non-Interventional Study
N. Blank,C. Schuetz,Markus Hufnagel,Gerd Horneff,Michael Borte,T. Kallinich,P. Oommen,Ales Janda,J. Henes,Julia Weber-Arden,Michael Stock,Jasmin B Kuemmerle-Deschner +11 more
TL;DR: This interim analysis of the RELIANCE study evaluates the long-term effectiveness and safety of canakinumab in 21 TRAPS patients, demonstrating well-controlled disease activity and no serious adverse reactions, supporting its use for TRAPS treatment.
Op0252 long-term safety and effectiveness of canakinumab in cryopyrin-associated periodic syndromes (caps) – 4-years data from the reliance registry
Jasmin B Kuemmerle-Deschner,Birgit Kortus-Goetze,Clara Schuetz,Prasad T. Oommen,Ales Janda,Juergen Rech,Frank Weller-Heinemann,Tilmann Kallinich,Alexis Pankow,Gerd Horneff,Ivan Foeldvari,Peter Wasiliew,Michael Forte,Michael Fiene,Franziska Meier,T. Krickau,I. Andreica,Julia Weber-Arden,Norbert Blank +18 more
TL;DR: In this paper , a prospective, non-interventional, observational study enrolls patients with clinically confirmed diagnoses of Cryopyrin-associated periodic fever syndromes (CAPS) routinely receiving CAN.